Skip to main content
Premium Trial:

Request an Annual Quote

Japanese Patent Office Grants Claims in Alnylam's Tuschl-II Application

Premium

Alnylam Pharmaceuticals said this week that the Japanese Patent Office has granted claims in a second patent application in the so-called Tuschl II patent series.

The application, No. 2006-317758, is entitled, "RNA Interference Mediating Small RNA Molecules," according to the company.

The patent "includes 38 claims broadly covering compositions, methods, uses, and systems for double-stranded RNAs having key structural elements that are widely recognized as important for the therapeutic activity of siRNAs," Alnylam said. The Japanese Patent Office granted a related set of claims in May last year, it noted.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more